TAK
NYSETakeda Pharmaceutical Company Limited
News · 26 weeks127-39%
2026-03-012026-08-23
Mix6990d
- Insider44(64%)
- SEC Filings13(19%)
- Other10(14%)
- Leadership1(1%)
- Earnings1(1%)
Latest news
25 items- PRORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda ((4502, NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor
- INSIDERPresident, R&D Plump Andrew Stewart sold $363,347 worth of American Depositary Shares (19,651 units at $18.49) as part of a pre-agreed trading plan (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Human Resources Officer Greenway Nicola Deidre Petal sold $235,118 worth of American Depositary Shares (12,980 units at $18.11), decreasing direct ownership by 24% to 40,049 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Medical Officer Farajallah Awny Samaan Botros sold $239,503 worth of American Depositary Shares (14,006 units at $17.10), decreasing direct ownership by 11% to 116,177 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, PDT BU Ibrahim Ramy Riad Ahmed sold $124,437 worth of American Depositary Shares (7,277 units at $17.10), decreasing direct ownership by 7% to 102,588 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, U.S. Business Unit Pacheco Rhonda Janice sold $289,007 worth of American Depositary Shares (16,901 units at $17.10), decreasing direct ownership by 8% to 182,507 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Transformation Officer Duprey Lauren Rusckowski sold $813,721 worth of American Depositary Shares (47,586 units at $17.10), decreasing direct ownership by 17% to 226,057 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, R&D Plump Andrew Stewart sold $2,828,220 worth of American Depositary Shares (165,393 units at $17.10), decreasing direct ownership by 18% to 766,569 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERHead, Strat. & Port. Dev Pignagnoli Agosti Marcello sold $392,565 worth of American Depositary Shares (22,957 units at $17.10), decreasing direct ownership by 11% to 176,977 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, OBU Bitetti Teresa Marie sold $855,205 worth of American Depositary Shares (50,012 units at $17.10), decreasing direct ownership by 17% to 252,010 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPres., Global Supply & Quality Shannon Elaine Mary sold $68,024 worth of American Depositary Shares (3,978 units at $17.10), decreasing direct ownership by 6% to 63,333 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Data & Tech. Officer Ricci Gabriele sold $429,005 worth of American Depositary Shares (25,088 units at $17.10), decreasing direct ownership by 13% to 171,654 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Human Resources Officer Greenway Nicola Deidre Petal sold $115,835 worth of American Depositary Shares (6,774 units at $17.10), decreasing direct ownership by 11% to 53,029 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident and CEO Kim Julie So-Young sold $1,523,439 worth of American Depositary Shares (89,090 units at $17.10), decreasing direct ownership by 19% to 391,489 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, IBU Platford Giles Richard sold $531,519 worth of American Depositary Shares (31,083 units at $17.10), decreasing direct ownership by 9% to 315,838 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERGlobal General Counsel Furney Natalie Anne Marie sold $527,843 worth of American Depositary Shares (30,868 units at $17.10), decreasing direct ownership by 13% to 204,298 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Human Resources Officer Greenway Nicola Deidre Petal sold $605,778 worth of American Depositary Shares (34,603 units at $17.51), decreasing direct ownership by 37% to 59,803 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPres., Global Supply & Quality Shannon Elaine Mary sold $357,371 worth of American Depositary Shares (20,363 units at $17.55), decreasing direct ownership by 23% to 67,311 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- PRU.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda ((TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- PRTakeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on TrackSolid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands Commercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFULTM (oveporexton) in China, setting the foundation for next wave of medicines No change to FY2026 full-year forecast and management guidance Takeda ((4502, NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing comme
- PRTakeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis StudiesOn average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda ((TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent ora
- PRTakeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal ProductsMinistry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi-Phased Initiative Takeda Will Initially Invest up to 30 Million U.S. Dollars to Begin the Establishment of an Ecosystem for Plasma-Derived Medicinal Products, including a pilot of a National Plasma Donation Network Collaboration Builds on Decades-Long Relationship Between Takeda and Indonesia Focused on Elevating Healthcare Standards for Patients Takeda (NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today a
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
TAK FAQ
7 questionsWhat does Takeda Pharmaceutical Company Limited do?
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD...Where does TAK stock trade?
Takeda Pharmaceutical Company Limited (TAK) is listed on NYSE.What sector and industry is TAK in?
Takeda Pharmaceutical Company Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Takeda Pharmaceutical Company Limited go public?
Takeda Pharmaceutical Company Limited (TAK) completed its IPO in 2018.What are analysts saying about TAK?
Takeda Pharmaceutical Company Limited has had 6 recent analyst actions on file. The most recent action was from Bernstein: Outperform on 2026-04-08. Recent price targets range from $2000.00 to $2400.00.What companies are similar to TAK?
Notable peers in the same industry include ABBV (AbbVie Inc.), AZN (AstraZeneca PLC), AMGN (Amgen Inc.), BMY (Bristol-Myers Squibb Company), SNY (Sanofi). Compare TAK side-by-side with any of them on Quantisnow.How can I track TAK on Quantisnow?
Quantisnow aggregates Takeda Pharmaceutical Company Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TAK to receive live email and push alerts on every new disclosure.